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Regulated intramembrane proteolysisThe Type III TGF-β receptor, betaglycan, is a widely expressed proteoglycan co-receptor for TGF-β superfamily
ligands. The full-length protein undergoes ectodomain cleavage with release of a soluble ectodomain
fragment. The fate of the resulting transmembrane–cytoplasmic fragment, however, has never been explored.
We demonstrate here that the transmembrane–cytoplasmic fragment is stable in transfected cells and in cell
lines expressing endogenous betaglycan. Production of this fragment is inhibited by the ectodomain shedding
inhibitor TAPI-2. Treatment of cells with inhibitors of the intramembrane protease γ-secretase stabilizes this
fragment, suggesting that it is a substrate of γ-secretase. Expression of the transmembrane–cytoplasmic
fragment as well as γ-secretase inhibitor stabilization are independent of TGF-β1 or -β2 and are unaffected by
mutation of the cytoplasmic domain serines that undergo phosphorylation. γ-Secretase inhibition or the
expression of a transmembrane–cytoplasmic fragment in HepG2 cells blunted TGF-β2 signaling. Our ﬁndings
thus suggest that the transmembrane–cytoplasmic fragment remaining after betaglycan ectodomain cleavage
is stable and a substrate of γ-secretase, which may have signiﬁcant implications for the TGF-β signaling
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The transforming growth factor-β (TGF-β) superfamily is a widely
expressed family of peptide growth factors with broad functions
including the control of cell growth, differentiation, and adhesion.
TGF-β superfamily members, including the TGF-βs, activin/inhibin,
the bone morphogenetic proteins (BMPs), and Müllerian inhibiting
substance, signal through pairs of structurally similar but functionally
distinct cell surface receptors, termed type I and type II receptors
(TGFRI and TGFRII), which have serine/threonine kinase cytoplasmic
domains. An additional TGF-β binding protein, known as the type III
TGF-β receptor or betaglycan, is a broadly distributed heparin and
chondroitin sulfate proteoglycan that acts as a signaling modiﬁer and
co-receptor [1–6]. Betaglycan is an important regulator of develop-ment and differentiation [7–12] and tumor growth and metastasis
[13–18] and can modulate MAPK signaling associated with TGF-β
activation [19,20]. Betaglycan binds all three TGF-β isoforms with
high afﬁnity through two distinct binding sites on the core
ectodomain [21]. Mechanistically, betaglycan enhances TGF-β depen-
dent signaling by increasing the afﬁnity of the ligand for TGFRII
[4,5,22]. This is particularly important for signaling by the isoform
TGF-β2, which, unlike the TGF-β1 and -β3 isoforms, has low afﬁnity
for TGFRII alone and appears to require the presence of preformed
TGFRI/TGFRII complexes in order to signal in the absence of
betaglycan [22–25].
Recent studies suggest that betaglycan has additional functions in
addition to enhancing TGF-β2 signaling. Superfamily members
inhibin and BMP-2 bind to the betaglycan ectodomain core, and
FGF-2 binds via the glycosaminoglycan (GAG) chains [1,26–30].
Betaglycan binds to inhibin, in some contexts mediating formation of
a complex with the type II activin receptor and thereby inhibiting
binding and signaling by activin [29–31]. Betaglycan serves similar
inhibitory functions in BMP-2 signaling by binding BMP-2 and, in
certain settings, has an inhibitory function in TGF-β signaling as well
[28,32,33]. Additionally, through the action of as yet undetermined
matrixmetalloproteinases, betaglycan undergoes ligand-independent
ectodomain shedding [34–36] with release of a stable soluble
Fig. 1. Betaglycan ectodomain cleavage results in the production of a stable
transmembrane–cytoplasmic domain fragment. A) COS-7 cells were transiently
transfected with the indicated betaglycan constructs or empty vector (V). Cells were
treated for 12–14 hours with 200 pM TGF-β1 or TGF-β2 in serum free medium.
Immunoblotting was carried out with α-BG/ecto and α-BG/cyto antibodies, as
indicated. Full-length HA-tagged betaglycan species (bracket) migrate as a combination
of a discrete band of 120 kDa, reﬂecting the N-glycosylated core protein, and as a smear
from ~140 kDa to above 200 kDa, reﬂecting the heterogeneously GAG-modiﬁed forms.
The TM/cytoplasmic domain fragment (arrowhead) migrates at 17 kDa. The doublet
seen for this construct likely represents variable cleavage of the short, HA-tagged
ectodomain and is not seen consistently. The blot was stripped and probed with an
antibody against cyclophilin B (CypB) as a loading control. The blot shown is
representative of three independent experiments.
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value in certain malignancies and ﬁbrotic diseases as an inhibitor of
TGF-β signaling [37–44]. In contrast to the ectodomain, the short (44
amino acid) betaglycan cytoplasmic domain, which lacks kinase
activity or identiﬁable signaling motifs, has not been well studied.
Some, although not all, studies suggest that deletion of the entire
cytoplasmic domain reduces TGF-β2 sensitivity [32,45]. Interactions
between the betaglycan cytoplasmic domain and other proteins,
including β-arrestin and the PDZ domain protein GIPC, can modulate
TGF-β signaling by various mechanisms, including activation of
alternative pathways [46,47] and endocytosis of other TGF-β
receptors [48–51]. The cytoplasmic domain of betaglycan also serves
as a modulator of TGF-β dependent and independent activation of
p38/MAPK through an undetermined mechanism [19,20,52]. The full-
length betaglycan forms a complex with syndecan-2, an interaction
that may be important in regulating TGF-β signaling in ﬁbrosis [53];
the syndecan-2 cytoplasmic domain appears to be required for this
interaction, although the role of the cytoplasmic domain of betaglycan
has not been determined.
Our goal was to investigate the fate of the betaglycan fragment
remaining after ectodomain cleavage. Many other transmembrane
receptors, including Notch, ErBb4, the insulin-related growth factor
receptor, theMet receptor, the p75neurotrophin receptor, and syndecan-
3 undergo ectodomain shedding followed by γ-secretase-mediated
intramembrane proteolytic cleavage. Many of the resulting free cytoplas-
mic domains have important functions independent of the full-length
receptors [54–61]. Ectodomain shedding is a prerequisite step
for cleavage of the receptor intracellular domain since the γ-secretase
complex preferentially cleaves single transmembraneproteinswith short
ectodomain regions [60,62,63].
We hypothesized that betaglycan, by virtue of undergoing
ectodomain cleavage, is also a substrate for γ-secretase. We provide
evidence here that the betaglycan transmembrane–cytoplasmic (TM/
cytoplasmic) fragment is stable, undergoes cleavage by γ-secretase,
and may have important effects on TGF-β signaling.
2. Materials and methods
2.1. cDNA constructs and cell lines
cDNA constructs used are shown in Supplemental Fig. 1. HA-tagged
full-length rat betaglycan (wtBG), a GAG-minus mutant (ΔGAG), and a
cytoplasmic domain minus mutant (ΔCyto) were constructed as
previously described [2,32]. Cytoplasmic domain residues Ser833,834
weremutated to Ala833,834 using the QuikChange II PCRmutagenesis kit
(Stratagene, San Diego, CA) to generate the ΔSer construct. An HA-
tagged ectodomain-minus receptor (ΔEcto) was constructed by ﬁrst
inserting ClaI restriction sites by site-directed mutagenesis at positions
87 and 2346 (numbering as per [6]) of the HA-tagged rat betaglycan
cDNA. The resulting cDNA was then digested with ClaI, the smaller
fragment (encoding the bulk of the ectodomain) removed, and the
larger fragment ligated closed. The resulting construct encodes a protein
with an ectodomain composed of the betaglycan signal sequence, the
two amino acids distal to the signal sequence, the nine amino acid HA
epitope tag, and the seven amino acids GluProSerAsnArgLeuAsp, plus
the complete betaglycan transmembrane and cytoplasmic domains. Cell
lines were obtained from the ATCC (COS-7, CR-1651; HepG2, HB-8065;
NIH-3T3, CRL-1658; CHO, CCL-61). cDNAs were introduced into COS-7
cells using the Effectene reagent (Qiagen, Valencia, CA) and into HepG2
cells using FuGENE 6 (Roche, Indianapolis, IN). Transfection efﬁciency
for HepG2 cells was approximately 15%–20%.
2.2. Inhibitor treatments and Western blotting
COS-7 cells 48 hours after transfection were incubated in serum
free media overnight with 200 pM TGF-β1 or TGF-β2 (R&D Systems,Minneapolis, MN), the γ-secretase inhibitors (GSI) X or XVII (100 nM
for COS-7, 1 μM for other cell lines; Calbiochem, La Jolla, CA), or
cycloheximide (10 μM; Sigma, St. Louis, MO). Some cells were treated
similarly for 14 hours with TAPI-2 (25 μM; Calbiochem). Cell lysates
were separated by SDS–PAGE followed by immunoblotting with
antibodies against the cytoplasmic domain of betaglycan (α-BG/cyto;
0.8 μg/mL; Santa Cruz Biotechnology, Santa Cruz, CA), the ectodomain
of betaglycan (α-BG/ecto; 0.5 μg/mL; R&D Systems), the HA epitope
tag (0.3 μg/mL; Sigma), or cyclophilin B (0.5 μg/mL; Afﬁnity Bior-
eagents, Rockford, IL). In addition to HRP conjugated secondary
antibodies, infrared conjugated secondary antibodies were used in
conjunction with the LI-COR Odyssey Infrared Imaging System (LI-
COR Biosciences, Lincoln, NE). Images of blots acquired with the
Odyssey system were adjusted to a gamma setting of 1.0 for use in
ﬁgures. Conditioned media from transfected COS-7 cells treated with
TAPI-2were concentrated and adjusted for protein levels based on the
protein concentration of corresponding cell lysates. Concentration-
adjusted media were then separated by SDS–PAGE for analysis of
soluble betaglycan ectodomain levels.
2.3. Dual luciferase assay
HepG2 cells were transfected with empty vector or ΔEcto
construct as well as the 3TP-lux [64] and Renilla luciferase (Promega,
Madison, WI) constructs. After 12–16 hours, cells were trypsinized,
re-seeded on 48 well plates, and incubated for an additional 12–
16 hours before being serum starved for 6 hours. They were then
treated with 30 pM TGF-β1 or -β2 and 1 μM GSI-X or XVII in serum
free media for 12–16 hours. Luciferase activity was assayed using the
Promega Dual Luciferase assay kit (Promega) and was corrected for
Renilla levels.
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3.1. Betaglycan ectodomain cleavage yields a stable transmembrane–
cytoplasmic fragment
We ﬁrst sought to determine whether ectodomain cleavage of
betaglycan results in production of a stable TM/cytoplasmic fragment.
Immunoblotting of lysates from COS-7 cells transfectedwith full-length
betaglycan demonstrated the presence of a speciﬁc band migrating at
17 kDa that was detectable using antibodies raised against the
betaglycan cytoplasmic domain (Fig. 1; lower panel) but not against
the ectodomain (Fig. 1, upper panel) or HA epitope tag (data not
shown). The artiﬁcial TM/cytoplasmic domain construct (ΔEcto),which,
unlike the endogenous TM/cytoplasmic fragment, carries an HA epitope
tag, was also stable and detected by immunoblotting (Fig. 1, lower
panel). Treatmentwith TGF-β1 or TGF-β2 did not alter the expression of
the TM/cytoplasmic domain fragment in COS-7 cells. Similarly, serine to
alanine mutation of the two residues in the betaglycan cytoplasmic
domain that undergo phosphorylation (ΔSer) did not change TM/
cytoplasmic fragment expression.
3.2. Gamma-secretase inhibitors stabilize the betaglycan
transmembrane–cytoplasmic domain fragment
The stability of the betaglycan TM/cytoplasmic domain fragment
suggested that it might be a substrate for γ-secretase. We there-Fig. 2. The betaglycan TM/cytoplasmic fragment can be stabilized by the addition of GSIs. A) CO
vector (V). Cells were treated for 12–14 hours with TGF-β2 (200 pM) and γ-secretase inhi
immunoblotting usingα-BG/cyto. Full-length betaglycan is indicated by brackets and the TM
an antibody against cyclophilin B as a loading control. B) Band densitometry of the TM/cyto
error. Signiﬁcance is in comparison to the no-treatment condition, determined by two-tai
indicated with or without 100 nM GSI-XVII in complete medium. Lysates from COS-7 cells w
antibody; representative blot of three. D) Band densitometry of the TM/cytoplasmic fragmen
treatment condition ±standard error (n=3 independent experiments; P=0.0001 by one-wfore treated COS-7 cells expressing various betaglycan constructs
with γ-secretase inhibitors. As was also observed in Fig. 1, treatment
with TGF-β did not signiﬁcantly alter the production of the TM/
cytoplasmic domain fragment (Fig. 2A and B). Addition of two different
γ-secretase inhibitors, however, resulted in signiﬁcant stabilization of
the TM/cytoplasmic fragment (Fig. 2A andB). Furthermore, stabilization
of this fragment persisted for at least 24 hours of GSI treatment (Fig. 2C
and D). Cycloheximide treatment in conjunction with γ-secretase
inhibitors resulted in a similar degree of TM/cytoplasmic domain
stabilization, indicating that appearance of this product is not due to
increased translation (Supplemental Fig. 2).
3.3. The TM/cytoplasmic fragment is stabilized by GSI treatment in cell
lines with endogenous betaglycan expression
γ-Secretase-mediated stabilization of the TM/cytoplasmic fragment
was also observed for HepG2, NIH-3T3, and CHO cell lines that express
betaglycan endogenously (Fig. 3). Interestingly, it was not observed for
Mv1Lu cells, which have been reported to demonstrate unusually low
levels of ectodomain cleavage (data not shown) [65]. Again, TGF-β1
treatment yielded no signiﬁcant changes in TM/cyto production or
stabilization, although there was a modest decline in stabilization with
TGF-β2 treatment in HepG2 cells. Interestingly and in contrast to COS-7
cells, theTM/cytoplasmic fragment is not visualized in the absence ofGSI
in any of the three cell lines, although all express betaglycan at high
levels.S-7 cellswere transiently transfectedwith the indicated betaglycan constructs or empty
bitors (GSI-X, GSI-XVII; 100 nM) in serum free medium and lysates were analyzed by
/cytoplasmic domain, by the ﬁlled arrowhead. The blot was stripped and re-probed with
plasmic domain from panel A. Data are from four independent experiments, ±standard
led paired t-test, *Pb0.05. C) COS-7 cells expressing ΔGAG were treated for the times
ere separated by 4%–20% gradient SDS–PAGE and immunoblotted with the α-BG/cyto
t for three replicate time courses is shown, with values expressed relative to 0 hour no-
ay ANOVA comparing the no-treatment and GSI curves).
Fig. 3. The TM/cytoplasmic fragment is stabilized in cell lines endogenously expressing betaglycan. A, C) The cell lines indicated were treated with TGF-β and GSI as in Fig. 2. Lysates
were split and separated on low (top panel) and high (middle panel) percentage SDS–polyacrylamide gels, and immunoblotting was carried out with antibodies against the
ectodomain (α-BG/ecto; top panel) and cytoplasmic domain (α-BG/cyto; middle panel) of betaglycan. The high percentage blot was re-probed with an antibody against cyclophilin
B (CypB; bottom panel). Brackets indicate full-length betaglycan; arrowheads indicate the TM/cytoplasmic domain fragment. The blots shown are representative of ﬁve independent
experiments. B) Band densitometry of the TM/cytoplasmic domain of the ﬁve replicate experiments of panel A ±standard error, signiﬁcance determined by two-tailed paired t-test,
*P≤0.05.
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transmembrane–cytoplasmic domain production
Inhibition of MT-MMP and ADAM proteases with TAPI-2 was
previously reported to reduce betaglycan ectodomain cleavage [36].
To conﬁrm these results in our own model system, we treated COS-7
cells expressing ΔGAG with TAPI-2. This resulted in a signiﬁcant
reduction in levels of the soluble betaglycan ectodomain (Fig. 4A and
B) but had minimal impact on the levels of full-length receptor
detected, suggesting that the percentage of receptor undergoing
ectodomain cleavage was small (Fig. 4C and D). Because γ-secretase
preferentially cleaves transmembrane receptors with short ectodo-
main regions [54,57,59,60,62,63], we assessed the impact of ectodo-
main shedding on production of the TM/cytoplasmic domain. As
expected, COS-7 cells expressing ΔGAG and treated with TAPI-2
demonstrated a reduced amount of TM/cytoplasmic domain com-
pared to untreated cells (Fig. 4C and E). Surprisingly, however,
treatment with GSI yielded the same amount of TM/cytoplasmic
domain regardless of whether TAPI-2 was present or absent (Fig. 4C
and E). This could be explained by a model in which a small
percentage of the full-length receptor undergoes ectodomain cleav-
age (as is suggested by Fig. 4A and C) while a large percentage of the
TM/cytoplasmic domain is cleaved by γ-secretase. It is signiﬁcant to
note that GSI treatment did not increase levels of soluble betaglycan
ectodomain (Fig. 4A and B), indicating that γ-secretase does not
promote ectodomain shedding and that full-length betaglycan is not a
preferred substrate.3.5. Inhibition of γ-secretase reduces TGF-β2 driven luciferase
HepG2 cells express endogenous betaglycan and exhibit a robust
response to TGF-β1 and -β2 as measured by a luciferase reporter assay
(Fig. 5). Co-treatment with either GSI-X or -XVII resulted in signiﬁcant
blunting of the response to TGF-β2, although not to TGF-β1 (compare
left sections of graphs, Fig. 5A and B). To determine whether the TM/
cytoplasmic fragment itself has any effect on the response to TGF-β, we
transfected HepG2 with ΔEcto as well as luciferase reporter constructs
(Fig. 5A and B). Over-expression of the TM/cytoplasmic domain
construct did not affect either the response to TGF-β1 or TGF-β2 alone
or the response to either growth factor in the presence of a GSI.
4. Discussion
We have demonstrated here for the ﬁrst time that ectodomain
cleavage of the TGF-β superfamily receptor betaglycan yields a stable
TM/cytoplasmic domain fragment and that this fragment is further
stabilized by GSI, suggesting that it is a target of the γ-secretase
complex. When initially identiﬁed, betaglycan was thought to be a
non-essential ligand co-receptor that bound TGF-β ligand and
enhanced signaling, particularly for TGF-β2 [3,4,6,34]. More recent
studies, however, have shown that betaglycan binds to multiple
members of the TGF-β superfamily of ligands and, by regulating
ligand–receptor access, can function as an agonist or antagonist of
signaling [1,21,26–33]. Our data suggest that the TM/cytoplasmic
fragment may mediate additional functions of betaglycan.
Fig. 4. TAPI-2 reduces ectodomain shedding and TM/cytoplasmic domain production. COS-7 cells expressing ΔGAG were treated overnight with 25 μM TAPI-2 and 100 nM GSI-XVII
in serum free medium. (ΔGAG was used for this experiment because of the ease of quantifying the ectodomain in the absence of the heterogeneous GAG modiﬁcations.) A)
Concentrated medium from treated COS-7 cells was separated on a 6% SDS–PAGE gel and immunoblotted with antibody against the ectodomain of betaglycan (α-BG/ecto), showing
the full-length core protein (open arrowhead). B) Densitometry of the 95 kDa betaglycan band shown in A, averaged from three independent experiments. Similar results were
observed by dot-blotting (data not shown). C) Lysates from COS-7 cells were separated by 4%–20% gradient SDS–PAGE and immunoblotted with antibody against the cytoplasmic
domain of betaglycan (α-BG/cyto), showing the full-length core protein (bracket) and TM/cyto domain (ﬁlled arrowhead). The lower panel is a long exposure of the lower region of
the gel shown in the upper panel. D, E) Densitometry from C of the full-length core domain of betaglycan (D) and the TM/cytoplasmic domain (E), averaged from three independent
experiments. Signiﬁcance determined by two-tailed paired t-test, *Pb0.05.
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[7,12], and the loss of betaglycan expression is permissive for tumor
growth [14–16,66]. Endoglin, another TGF-β-binding accessory
receptor with 63% homology to betaglycan in the transmembrane
and cytoplasmic domains [3,67,68], is similarly important function-
ally: mutations in endoglin are responsible for the autosomal
dominant disorder hereditary hemorrhagic telangiectasia syndrome,
which is characterized by multiple vascular defects [69,70]. Knockout
mice have conﬁrmed that endoglin plays an essential role in
angiogenesis [71].
There is substantial evidence in the literature that the endoglin
cytoplasmic domain is functionally important. Endoglin is found in two
forms, L-endoglin,with a47aminoacid cytoplasmic tail, and S-endoglin,
with a 14 amino acid tail. Exogenous expression of the two forms has
different effects on TGF-β signaling, suggesting the possibility of an
independent function for the cytoplasmic domain [72]. Many endoglin
mutations found in HHT result in impaired coordination of TGF-β
signaling complexes, inwhich the cytoplasmic domain has a critical role[69,70,73]. Studies have also implicated the endoglin cytoplasmic
domain in the control of cell migration and focal adhesion complex
composition through interaction with the LIM domain of zyxin [74].
Although betaglycan does not interact with zyxin, the structural
homology between the betaglycan and endoglin cytoplasmic domains,
including the paired serine motif that undergoes phosphorylation in
betaglycan and the C-terminal PDZ-binding domain which interacts
with GIPC family PDZ domains [48], suggests an overlapping role for the
betaglycan cytoplasmic domain in TGF-β signaling.
Multiple signaling pathways require ectodomain shedding and γ-
secretase-dependent release of an intracellular domain. One implica-
tion of the work reported here is that these processes are similarly
important in TGF-β signal transduction. The TM/cytoplasmic fragment
and the isolated cytoplasmic domain of betaglycan might both serve
important functions. Our data (Fig. 5A and B) show that γ-secretase
inhibition has a signiﬁcant impact on TGF-β signaling. Although these
effects could result from inhibiting the intramembrane cleavage of
other receptors, betaglycan appears the likely target. The possibility
Fig. 5. Inhibition of γ-secretase reduces TGF-β2 signaling. A, B) HepG2 cells were
transfected with either pcDNA (vector) or ΔEcto as well as 3TP-lux and Renilla
luciferase constructs. Luminescence was measured after a 14 hour treatment in 30 pM
A) TGF-β1 or B) TGF-β2 with 1 μM GSI-X or GSI-XVII. Values were normalized using
Renilla controls and are expressed relative to the no-treatment condition ±standard
error; signiﬁcance determined by repeated measures ANOVA with Dunnett's post test,
*Pb0.05; n=18 for each condition (6 replicates per experiment, 3 independent
experiments).
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ectodomain, TM/cytoplasmic domain, and isolated cytoplasmic
fragment) have opposing effects on TGF-β signaling suggests a
possible model whereby TGF-β acts over a narrow concentration
range, with betaglycan serving as a “molecular switch.”
γ-Secretase cleavage of the TM/cytoplasmic fragment is presumed
to result in release of an isolated cytoplasmic fragment. We have been
unable to visualize this fragment even in the presence of high doses of
proteasomal and lysosomal inhibitors, suggesting that it is highly
unstable, as is the case for other cytoplasmic domains that are the
products of γ-secretase-mediated cleavage [54]. The function of the
isolated betaglycan cytoplasmic domain is unknown, although
inhibiting its release appears to decrease TGF-β signaling (Fig. 5A
and B). Interactions with the cytoplasmic domain—possibly mediated
through its phosphoserines or PDZ-binding domain—may be neces-
sary for activation of downstream signaling molecules following
release by γ-secretase. The cytoplasmic domain does not contain a
known nuclear localization signal, although that does not preclude
shuttling to the nucleus via interactions with other proteins.
The identiﬁcation of the three TGF-β receptors and initial
elucidation of the Smad pathway suggested a surprisingly and
elegantly simple signaling pathway for TGF-β signaling. The identi-
ﬁcation of variant pathways, however, including MAPK pathways via
Smad [52,75,76] and TAB-1/TAK-1 activation [77], add a level ofcomplexity to TGF-β signaling. There is signiﬁcant evidence that the
cytoplasmic domain of betaglycan is an essential component of TGF-β
related activation of the p38/MAPK pathway [19,20,52], and we
speculate that betaglycan plays a role in mediating the speciﬁcity of
TGF-β signaling pathways. Future work will concentrate on deﬁning
these mechanisms in more detail, as well as determining the
modulatory role of betaglycan in signaling by other TGF-β superfamily
members.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.12.005.
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